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The paper presents a review of the sequence of events of posterior vitreous detachment (PVD), vitreomacular adhesion (VMA),
vitreomacular traction (VMT), and macular hole (MH) from their pathophysiological aspects, clinical features, diagnostic
implications, and currentmanagement strategies. A treatment algorithm to be used in clinical practice in patients with VMA, VMT,
andMH based on the presence of symptoms, visual acuity, associated epiretinal membrane, and width of the vitreous attachment is
presented. Observation, pharmacologic vitreolysis with ocriplasmin, and surgical treatment are positioned as treatment options in
the different steps of the therapeutic algorithm, with clear indications of the paths to be followed according to the initial presenting
manifestations and the patient’s clinical course.
1. Introduction
Posterior vitreous detachment (PVD) is a common phe-
nomenon frequently related with aging of ocular structures
[1].The presence of persistent vitreomacular adhesions exert-
ing tractional forces (vitreomacular traction, VMT) may be
associated with the development of macular hole (MH) [2,
3]. These alterations in the symptomatic phase may cause
visual disturbances, including photopsia, metamorphopsia,
blurred vision, and decreased visual acuity, which in addition
of causing visual-related problems may affect negatively the
patient’s health-related quality of life [4]. The introduction
of optical coherence tomography (OCT) has allowed a more
accurate visualization of the macular anatomy and better
knowledge of the pathophysiology of the process, including
measurement and assessment of MH characteristics [5–7],
facilitating treatment decision-making.
1.1. Anatomy of the Vitreous and the Vitreoretinal Interface.
The vitreous gel is responsible for the stabilization of the
eyeball through collagen fibers (mainly type II collagen).
Collagen fibers are running in an anteroposterior direction
through the vitreous center, convering in the anterior vit-
reous base, and inserting into the posterior vitreous cortex
[8]. Spaces between the collagen fibrils are maintained by
the protein opticin and the glycosaminoglycan chondroitin
sulphate [4]. Spaces between the collagen fibrils are mostly
filled with water (98% of the vitreous gel component) and
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The vitreoretinal interface is a complex anatomical struc-
ture composed by the union between the retina and the
vitreous [9]. Densely packed collagen fibrils of the pos-
terior vitreous cortex (100–300 𝜇m in thickness) lie over
the macula and are superficially inserted into the internal
limiting membrane (ILM) of the retina by means of adhesion
molecules, such as laminin, fibronectin, and proteoglycans,
which interact with opticin in the vitreous gel [4]. Adherences
are more firmly attached to the retina at the vitreous base,
optic disc, and fovea, as well as along the major retinal blood
vessels. The vitreomacular junction has an annular shape,
with a diameter of 3-4mm.
The set of events that occur as the eye ages are associated
with a series of physiological changes in the vitreous gel, with
progressive liquefaction (at the age of 80, around 50% of the
vitreous gel has been liquefied) and gradual destruction of
the collagen-hyaluronic acid network [10]. This occurs as a
result of the development of fluid-filled pockets beginning in
front of themacula, which over the time coalesce and enlarge,
resulting in a weakened adhesion between the vitreous and
the retina. This gradually predisposes to PVD, defined as
separation of the posterior cortex from the ILM of the retina,
which represents the final step of the normal vitreous aging
process [11, 12].
PVD is an insidious process that occurs over the course
of months or years, being asymptomatic in many cases until
complete separation of the vitreous from the macula and
optic nerve, which is the final stage. However, the anterior
attachment to the vitreous base is very strong and remains
for a long time. Acute symptoms of complete PVD include
photopsia (by vitreous traction on the peripheral retina) and
floaters by condensation of the vitreous collagen, glial tissue,
or blood around the optic nerve [4].
Studies in healthy adults have shown that focal perifoveal
PVD occurs in 50% of subjects aged between 30 and 39,
whereas complete PVD is found in 50% of subjects aged 70
years or older [13, 14]. In addition to advanced age, PVD
is more frequent in postmenopausal women by the effects
of decreased estrogens on the connective tissue (within the
vitreous gel), as well as in the presence of myopia [4].
The normal process of PVD due to vitreous aging may
be complicated by the presence of vitreomacular adhesions
between the cortex and the macular area, resulting from
vitreous syneresis [15]. These adherences may be focal or
extensive, affecting the foveola only or a wide region of
the macular area and the optic disc. Simple vitreomacular
adhesion (VMA) is not associated with distortion of the
macular architecture. However, these adherences may exert
traction forces on the macula (VMT), increasing secondarily
during ocular saccades [16].This may cause retinal distortion
and foveal detachment. On the other hand, continuous
anteroposterior traction by vitreous contraction may cause
alterations, such as cystoid macular edema.
Full-thickness MH is an anatomic defect in the fovea
with interruption of all neural retinal layers [17]. With
the use of high-resolution OCT, it has been shown that
idiopathic MHs are initiated during perifoveal PVD as a
consequence of the dynamic anteroposterior VMT process.
This anteroposterior VMT may cause intraretinal cavitation
with progression to dehiscence of the outer retinal layers
and complete detachment of the cyst roof giving rise to a
full-thickness defect. Stages of the development of MH from
focal VMT to complete aperture together with accompanying
symptoms have been described by Gass [18, 19].
The introduction of enzymatic vitreolysis [20], which can
result in the liberation of VMT, opens highly interesting new
perspectives in this field.
1.2. Risk Factors and Epidemiology of VMT. A few studies
have been specifically addressed to the epidemiology of
idiopathic VMT due to the overlapping of this condition
with other ophthalmological diseases [4]. A prevalence of
isolated idiopathic VMT, without MH, has been estimated
as approximately 22.5 cases per 100 000 of the general pop-
ulation, with an incidence of 0.6/100 000 persons-year [21].
In different observational and intervention studies, the mean
age of patients with VMTwas around 65–70 years (range 48–
64), with a predominance of females [4, 15].
Regarding the prevalence of MH, it has been reported
around 0.1 to 0.8 in adults aged >40 years [22], with an age-
adjusted incidence of 7.8 cases per 100 000 of the general
population per year [23]. Also, the risk of development ofMH
in the fellow eyes, without manifestations of PVD, has been
estimated at around 7–12% after 5 years and 17% at 20 years
[4].
Approximately two-thirds of patients with MH are
women, and the disease is unilateral in 80% of cases. An
increase in serum fibrinogen level has been reported as a risk
factor for MH [24], whereas the use of estrogen replacement
therapy in women decreases the risk [4]. In subjects with
myopia, the prevalence of MHmay reach 6% [25].
2. Diagnosis, Definition, and Classification of
VMT and MH
Now, nearly two decades since the introduction of OCT, it
is possible to assess and define the pathologic progression of
disorders affecting vitreoretinal interface with a high level of
accuracy and reproducibility. On the basis of OCT-derived
anatomic findings, a unified classification scheme for disease
of the vitreomacular interface has been developed.
With this purpose, a group of experts in diseases of the
vitreoretinal interface (International Vitreomacular Traction
Study Group, IVTS) [26] have proposed a classification sys-
tem for diseases of the vitreomacular interface.This evidence-
based classification is a clinically applicable system that is
predictive of therapeutic outcomes and is useful for the
execution and comparative analysis of clinical studies.
2.1. VMA. VMA represents a specific stage of partial vitreous
detachment in the perifoveal area without retinal abnormal-
ities. In previous classifications, VMA is the equivalent of a
stage 1 PVD [11, 15, 27, 28]. VMA is characterized by elevation
of the cortical vitreous above the retinal surface, with the
vitreous remaining attachedwithin a 3mmradius of the fovea
(as defined arbitrarily). The angle between the vitreous and
the inner retinal surface is acute, and the retina displays no
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abnormalities in contour or morphological features of OCT.
VMA is not accompanied by visual impairment and may be
considered a normal finding in the natural course of PVD.
Also, VMA may be subclassified by the size of the adhesion
into focal (≤1500𝜇m) or broad (>1500 𝜇m). The cutoff of
1500𝜇m corresponds to the area of increased vitreous adhe-
sion to the fovea. VMAusually resolves spontaneously as part
of the normal process of PVD, although it may progress to
VMT and, for this reason, periodic monitoring with OCT is
necessary.
2.2. VMT. Macular traction due to progression of PVD
causes anatomic changes in contour of the foveal surface,
intraretinal pseudocyst formation, and disappearance of
foveolar depression, which typically results in reduced or dis-
torted vision. The following anatomic criteria [26] should be
present at least in one OCT image to classify an eye as having
VMT: (a) evidence of perifoveal vitreous cortex detachment
from the retinal surface, (b) attachment of the vitreous cortex
to the macula within a 3mm radius of the fovea, and (c)
association of this attachment with distortion of the foveal
surface, intraretinal structural changes, foveal detachment
from the retinal pigment epithelium (RPE), or a combination
of these findings, without full-thickness interruption of all
retinal layers. VMT can also be subclassified as focal or
broad (using the same cutoff of 1500𝜇m) depending on the
width of the vitreous attachment. Distortion of the foveal
profile, formation of intraretinal cysts, intraretinal cavitation,
subretinal fluid, and, even, RPE detachment can be observed.
On the other hand, proliferation of residual of vitreous
tissue provides the anatomic substrate to form an epiretinal
membrane (ERM), which in turn may appear at any stage
of vitreous separation. ERM is composed of retinal pigment
epithelial cells, fibroblasts, and macrophages. ERM may
be associated with peripapillary vitreoretinal traction with
blurred disc border.
Although spontaneous resolution of VMT may occur,
traction on a large surface or the presence of ERM is
poor prognostic factor. In symptomatic patients, enzymatic
vitreolysis or vitrectomy may be indicated.
2.3. MH. As stated above, full-thickness MH is an anatomic
defect in the fovea featuring interruption of all neural retinal
layers. The observation of the anatomic opening on several
scans through the fovea is an unequivocal sign. According
to the aperture size, MHs are considered small (<250𝜇m),
medium (250 to 400 𝜇m), and large (diameter > 400𝜇m).
Nearly half of full-thickness MHs are large at the time of
diagnosis [26]. Also, on the basis of OCT findings, MH can
be categorized according to the presence or absence of VMT.
Only patients withMHand concomitantVMTare candidates
for pharmacologic vitreolysis. The correlations between MH
stages commonly used in clinical practice and OCT-based
images proposed by the IVTS group are shown in Table 1.
Moreover, MH can be subdivided into idiopathic and
secondary. Primary MH results from vitreous traction on
the fovea from anomalous PVD (incomplete or inadequate
separation of the vitreoretinal interface), whereas secondary
Figure 1: Horizontal image with swept-source OCT at the
foveal level showing posterior vitreous detachment, which remains
adhered to the fovea and the papillary edge.
MHs are caused by other pathologic conditions and do not
have preexisting or concurrent VMT. Secondary MHs have
been reported in cases of blunt ocular trauma [29], lightning
strike [30], highmyopia [25, 31],macular schisis [32],macular
telangiectasia type 2 [33], occlusion of the central retinal vein,
diabetic macular edema, uveitis, and age-related macular
degeneration [26].
3. Treatment Options
3.1. Observation. The availability of OCT, particularly spec-
tral domain OCT (SD-OCT), has allowed a more accurate
diagnosis and precise assessment of adhesion of the vitreous
to the macula, differentiating VMA from VMT [26]. Before
the introduction of OCT, only patients with advanced VMA
could have been diagnosed by biomicroscopy and, for this
reason, the rates of spontaneous deterioration reported were
high (64%) [34].
Studies using SD-OCT have shown that incomplete vit-
reous detachment with persistent vitreoretinal adhesions is
more frequently observed than by clinical diagnosis. During
the physiological process of PVD, the vitreous remains
attached to the foveal region in the last stages (Figure 1), so
that, VMA can be considered a normal stage in the natural
history of PVD associated with vitreous aging [13, 26]. Only
when symptoms are present or when foveal anatomic changes
are observed, VMA can be considered a pathological process
[34].
Recently, John et al. [35] investigated the spontaneous
clinical course in 106 eyes of 81 patients identified as having
VMA by SD-OCT and classified into three grades, with a
mean follow-up of 18 months (range 1 to 91). The authors
defined three grades to classify adherence: Grade 1 (41%) was
incomplete cortical vitreous separation with attachment at
the fovea, Grade 2 (52%) was the Grade 1 findings and any
intraretinal cysts, and Grade 3 (7%) was the Grade 2 findings
and the presence of subretinal fluid. By the last follow-up,
spontaneous release of VMA occurred in 32% of cases (34
eyes, in 30%, 30%, and 57% of Grades 1, 2, and 3, resp.). No
changes were observed in 23, 31, and 2 eyes (52% of the total),
and progression occurred in 7, 8, and 1 eye of Grades 1, 2,
and 3, respectively (16% of the total). The authors conclude
that the clinical course of patients with VMA managed by
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Table 1
Gass classification OTC findings Classification IVTS
Stage 0 Minimal changes in the foveal contour with perifovealdetachment of the perifoveal vitreous cortex without traction VMA
Stage 1A: imminent MH
Foveal cysts and sensory foveolar detachment associated with
perifoveal detachment with traction of the posterior vitreous
on the foveal internal limiting membrane
VMT
Stage IB Cyst in the outer retina causing rupture of the cones layer.Perifoveal detachment of posterior vitreous VMT
Stage 2: small MH
Full-thickness MH of small diameter, with partial rupture of
the internal wall of the cyst. Partial detachment of the
posterior vitreous, which still remains adhered to the
operculum
FTMH small/medium with VMT
Stage 3: large MH
MH of a larger size. Total detachment of the posterior
vitreous at the level of the macular area, which persists
adhered to the papilla. Occasionally, a free operculum
adhered to the posterior vitreous can be seen
FTMHmedium/large with VMT
Stage 4: full-thickness MH with
PVD
Total detachment of the posterior vitreous. In some cases, the
vitreous is not observed on OCT scans. Larger diameter of




FTMH: full-thickness macular hole, MH: macular hole, OCT: optical coherence tomography, PVD: posterior vitreous detachment, VMA: vitreomacular
adhesion, and VMT: vitreomacular traction.
Figure 2: Study of the retinal surface with swept-source OCT
showing posterior vitreous detachment, which remains attached at
the papillary level.
initial observation was generally favourable in asymptomatic
patients or with minimal symptoms of VMT.
Studying the retinal surface with SD-OCT, it has been
observed that PVD appears to begin in the perifoveal region,
with a slow clinical course taking even years until complete
separation of the vitreous from the papilla (Figure 2). Inmost
patients this process is asymptomatic but, in some cases,
PVD may be complicated by macular pathology [2]. In a
OCT study of eyes with macular edema secondary to VMT,
published in 2012, complete and spontaneous resolution of
traction was observed in 53% of eyes [36].
The clinical course of VMA, particularly in asymptomatic
patients, remains to be fully elucidated. Systematic examina-
tion with SD-OCT has been associated with an increase in
diagnostic rates and has allowed assessing more accurately
the course of this physiological process that may evolve into
VMT, remain stable, or resolve spontaneously. Therefore, in
the presence of a VMA syndrome, the first approach is to
reexamine the patients using OCT at a period of 3 months.
Even in cases of evolution to a VMT syndrome, observation
still remains an option, given the possibility of spontaneous
resolution of VMT.
3.2. Pharmacologic Vitreolysis: Ocriplasmin. Ocriplasmin is a
truncated form of human plasmin that induces liquefaction
of the vitreous and separation of the vitreous cortex from
the retinal surface due to proteolytic activity against main
components of the vitreomacular adhesion.
3.2.1. Results of Clinical Trials of Ocriplasmin and Initial Data
in Clinical Practice. The efficacy and safety of ocriplasmin
have been evaluated in two pivotal, phase 3 clinical trials
(TG-MV-006 y TG-MV-007) carried out in the United States
and Europe [20]. Both studies were very similar except for
the ratio of randomized assignments to ocriplasmin and
placebo, which was 2 : 1 in the TG-MV-006 study and 3 : 1 in
the TG-MV-007. Overall, 652 patients were randomized, 464
were assigned to treatment with a single intravitreal injection
of ocriplasmin (125 𝜇g) and 188 to a placebo intravitreal
injection. The primary endpoint was the pharmacologic res-
olution of VMA at day 28, as determined by OCT. Secondary
endpoints included the percentage of patients with complete
PVD and nonsurgical closure of full-thickness MH at day
28. Eligible patients had symptomatic focal VMA as seen
on OCT and a best-corrected visual acuity of 20/25 or less.
Exclusion criteria were high myopia (more than −8 diopters
or axial length > 26mm), prior vitrectomy or prior laser
photocoagulation of the macula, and other eye diseases that
may affect visual acuity. Patients with a MH > 400 𝜇m in
diameter were also excluded.Of note, the presence of an ERM
was not a criterion for exclusion.
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At day 28, VMA resolved in 26.5% of ocriplasmin-
injected eyes and in 10.1% of placebo-injected eyes (𝑃 <
0.001). The between-group differences did not change sub-
stantially at 6 months (26.9% ocriplasmin versus 13.3%
placebo, 𝑃 = 0.001). Also, 72% of patients with resolution of
VMA showed the release during the first seven days. Results
of adhesion release were better in patients without ERM
(37.4% in the ocriplasmin group versus 14.3% in the placebo
group, 𝑃 < 0.001).
With regard to secondary variables (day 28), 13.4% of
patients treated with ocriplasmin showed total PVD as
compared to 3.7% of those treated with placebo (𝑃 < 0.001).
Also, nonsurgical closure of full-thickness MH was achieved
in 40.6% of ocriplasmin-treated patients and in 10.6% of
placebo-treated patients (𝑃 < 0.001).
According to the investigator’s criteria, all patients could
be treated with vitrectomy in the framework of the study
if macular disease did not resolve. At 6 months, vitrectomy
was performed in 17.7% of patients in the ocriplasmin group
and in 26.6% of those in the placebo group (𝑃 = 0.02). At
6 months, there were statistically significant differences in
favour of ocriplasmin in the gain of two or more lines (23.7%
versus 11.2%, 𝑃 < 0.001) or three or more lines (12.3% versus
6.4%, 𝑃 = 0.02).
Important safety-related problems were not observed.
Most adverse events were related to the development of PVD
induced by ocriplasmin injection (floaters and photopsia).
There was a slightly higher incidence of retinal tears or
detachments in the placebo group, which was attributed
to the higher proportion of patients treated by means of
vitrectomy in this group.
The favourable results obtained in both clinical trials
allowed approval of the use of intravitreal injection of
ocriplasmin for the treatment of symptomatic VMT andMH
by the Food and Drug Administration (FDA) in the United
States, in November 2012, and by the European Medicines
Agency (EMA) in May 2013.
Outside the context of clinical trials, recent reports have
provided data of the use of ocriplasmin in daily practice. In a
retrospective study [37], 17 patients with symptomatic VMT
were treatedwith a single intravitreal injection of ocriplasmin
0.125mg. By day 28, resolution of VMT was verified by
SDOCT in eight patients (47.1%), 7 of which (87.5%) had
already experienced release by day 7.Those who did not have
traction release showed no statistically significant change
in VMA diameter. Four of the five patients (80%) with
MH at baseline experienced resolution of their MH after
injection. Significant differences in visual acuity were not
observed (20/49 at baseline and 20/46 at final follow-up).
It should be noted that patients meeting the four positive
predictor criteria (younger than 65 years, no ERMat baseline,
traction<1500𝜇m, and phakic lens status) showed a response
rate of 75% (three of four eyes). Transient outer segment
ellipsoid zone loss was documented in 7 cases (41.1%) and
subretinal fluid presence following injection was noted in 5
cases (29.4%) [37].
In another study of 19 patients with symptomatic VMA
treated with intravitreal ocriplasmin, resolution of VMA was
observed in 8 cases (42%) [38]. Results were significantly
affected by lens status, with adhesion release in 53% of
phakic patients, whereas no case of resolution of adhesions
was observed in pseudophakic patients. Also, closure of
MHs after treatment was found in 3 of 6 patients (50%).
Visual acuity remains stable, with a slight tendency towards
improvement in the majority of cases. Only one patient
showed an important loss of visual acuity (from 20/70 to
20/200) due to progression of VMT to a full-thickness MH.
Significant adverse events were not recorded.
3.2.2. Safety Profile. The safety profile of ocriplasmin has
been evaluated in the two pivotal trials [20]. The proportion
of patients who had any ocular adverse event was 68.4%
in the ocriplasmin group and 53.5% in the placebo group
(𝑃 < 0.001). This difference was driven primarily by adverse
events known to be associated with PVD.The most common
complications included vitreous floaters (ocriplasmin 16.8%
versus placebo 7.5%, 𝑃 = 0.002), photopsia (11.8% versus
2.7%,𝑃 < 0.001), blurred vision (8.6% versus 3.2%,𝑃 = 0.01),
and visual impairment (5.4% versus 1.6%, 𝑃 = 0.02). Most
of these adverse events were transient and mild in severity.
There were no differences between the groups in terms of
severe ocular adverse events, including development of MH
(5.2% versus 8.6%), retinal detachment (0% versus 1.6%), and
reduced visual acuity (0.6% versus 0.5%).
However, since the real-world use of the drug began, there
have been some unfavourable reports of visual disturbances
after ocriplasmin injection, including transient but profound
visual decline, raising concerns regarding its safety. Of 976
patients receiving ocriplasmin injection in clinical trials, 9
patients were reported to have experienced an acute decrease
in vision, some to the hand motions level, within 24 hours
of injection [39]. In 8 of these 9 patients, vision returned
to baseline with a median recovery time of 2 weeks. In
the clinical trials of ocriplasmin, dyschromatopsia, and elec-
troretinographic (ERG) changes occurred in a significantly
greater number of eyes treated with ocriplasmin than in eyes
receiving placebo [20, 40].
Freund et al. [41] recently reported a single case report
demonstrating changes seen in the outer photoreceptor seg-
ments by SD-OCT. The disruption occurred in the ellipsoid
zone andwas reversible. Since the clinical trials [20] used only
time-domain OCT with inferior resolution to SD-OCT, it is
possible that these cases may have been overlooked.
In another study in which 17 patients were included [37],
almost all the patients who responded to the treatment (7/8)
had ellipsoid zone changes on the SD-OCT (Figure 3). These
patients also had transient reduction of visual acuity and
demonstrated subretinal fluid during the release process with
almost the exact time course as the loss of the OS ellipsoid
zone. The loss of the OS ellipsoid zone occurred after an
average of 5 days after injection of ocriplasmin and the mean
time of resolution on OCT was 29.3 days. The occurrence
and resolution of subretinal fluid occurred at an average of
4.8 days and 30 days after injection, respectively. However,
in a retrospective review of 62 eyes with symptomatic VMA
treated with ocriplasmin, subretinal fluid appeared in 37%
of cases, with persistence of fluid in 30% of cases after 5
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Figure 3: (a) Focal VMT. The arrow points to the ellipsoid zone. (b) Release of VMT after injection of ocriplasmin. A severe disruption in
the ellipsoid zone is shown (by courtesy of Dr. Peter K. Kaiser, Cleveland Clinic, Cleveland, OH, USA).
months of follow-up [42]. Other studies have also shown
resolution of the ellipsoid zone changes in most patients
within weeks or months after ocriplasmin injection [43,
44].
Alteration of the ellipsoid zone on SD-OCT and a signif-
icant decrease in ERG amplitudes have been also reported
in two patients with release of symptomatic VMT after
ocriplasmin injection [45, 46]. It is possible that this transient
effect of the medication may be due to a diffuse enzymatic
effect of the protease on the photoreceptors or the retinal
pigment epithelium throughout the retina.The greater reduc-
tion in scotopic function compared with photopic function
suggests that rod photoreceptors may be more susceptible
than cone photoreceptors to the effects of ocriplasmin. If
this transient affect occurs for both rods and cones, it may
explain the dyschromatopsia, contrast sensitivity changes,
dark adaptation issues, and ERG changes reported in the
ocriplasmin clinical trials.
An ongoing phase 3b, 24-month randomized clinical trial
whichwill evaluate ERG andmicroperimetry in ocriplasmin-
treated eyes compared to sham, will provide additional clari-
fications on the observed EGR changes and dyschromatopsia
events (OASIS Study; NTC01429441) already reported.
3.3. Surgical Treatment
3.3.1. Peeling of the Internal Limiting Membrane. Surgery of
idiopathic MH with ILM peeling is a very safe procedure,
with good anatomic and functional results and scarce post-
operative complications [47]. Data provided by clinical trials
have shown that peeling of the ILM significantly increases
MH closure rates and is also associated with significantly
lower percentages of reoperation and reopening. Therefore,
ILM peeling is a cost-effective technique and the procedure
of choice for all patients with idiopathic full-thickness MH
susceptible to undergo surgical treatment [48–53].
Broad ILM peeling to the vascular arcades is recom-
mended, so that tangential traction forces on the MH edges
are removed facilitating approximation and closure [54]. In
cases of large MH (>400 𝜇m) with increased risk of failure of
primary surgery, alternative techniques have been proposed,
such as the inverted ILM flap technique in which instead
of completely removing the ILM, a remnant attached to
the margins of the MH is left in place. This ILM remnant
is then inverted upside down to cover the MH [55]. With
the use of this technique closure rates of 98% compared
to 88% with the standard technique have been achieved
[55]. For refractory MH to the standard technique or for
secondary MH after vitrectomy when peeling of the ILM has
been already performed, an autologous transplantation of the
ILM remnants introduced into the hole with subsequent gas
tamponade contributes to the improvement of anatomic and
visual outcomes [56].
3.3.2. Vital Dyes for ILM Staining. Vital dyes have become
effective and useful tools for identifying ocular tissues during
vitrectomy, thereby facilitating ILM peeling and ensuring
complete removal of this delicate membrane [57]. The most
frequently used vital dyes include triamcinolone acetonide
suspension in balanced salt solution (BSS) (Triesence), indo-
cyanine green and infracyanine green, brilliant blue, and
trypan blue with brilliant blue (Membrane Blue-Dual).
Triamcinolone suspension in BSS is not a true dye but is
very useful for the identification of vitreous remnants and
the posterior hyaloid. Deposition of crystals on the ILM
surface helps the achievement of complete removal of the
membrane, although it is less effective than vital dyes because
triamcinolone does not increase the rigidity of ILM.
Indocyanine green and infracyanine green possess a great
affinity for the matrix components of the ILM and produce
intense staining of the ILM. Besides the ability of indocyanine
and infracyanine green to stain the ILM, they cause an
increase in the biomechanical stiffness of the ILM, thereby
facilitating its peeling. Although in Europe they are no longer
used because of potential toxicity, they continue to be used in
the United States [58, 59].
Brilliant blue has a remarkable affinity for the ILM and,
although ILM staining is less intense than that achieved with
indocyanine green, causes adequate staining of the ILM and
may be used without fluid-air exchange. In Europe, it is
considered the best one for ILM peeling in MH surgery.
The combination of trypan blue and brilliant blue allows
staining of the ERM, posterior hyaloid, and ILM simultane-
ously. This combination has a lower density than water and
BSS and circumvents the need for fluid-air exchange. This
dual dye is extensively used in Europe [60].
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3.3.3. Tamponade and Postoperative Positioning. There is
controversy regarding posturing in MH surgery. Although
most authors recommend face-down posturing 90% of time
for 10 days, different studies have reported successful hole
closure in the absence of face-down positioning, given that
isolation of the macula by gas tamponade maintaining the
macula dried seems to be the most important factor for
closure [61–63]. In this respect, OCT studies have shown
that hole closure occurs during the first postoperative day
independently of the types of gas tamponade and posturing
[64], so that after vitrectomy with wide ILM peeling, gas
tamponadewould be sufficient (preferably short-acting gases,
such as SF6) at nonexpansible concentration, without the
need of face-down posturing, avoiding the prone position
during 3 to 5 days. This approach may be also indicated
for phakic patients because it does not seem to increase the
incidence of cataracts [54].
3.3.4. Combined Phacovitrectomy. Combined phacovitrec-
tomy or sequential vitrectomy and phacoemulsification are
safe and effective for the treatment of MH, with equivalent
anatomic and functional results [65]. In most cases, idio-
pathic MH affects patients older than 50 years in which
some degree of lens opacity is frequent. Moreover, cataract
develops in 75% to 95% of patients undergoing vitrectomy
for MH within 3 years after surgery. For this reason, most
authors recommend combined phacovitrectomy in patients
over 50 years of age. Both cost and discomfort are lower
with a single surgical procedure, and functional recovery is
more rapid. Combined phacovitrectomy may also decrease
the risk of reopening after cataract extraction in the two-step
surgical approach [66, 67]. However, combined vitrectomy,
phacoemulsification, and intraocular lens (IOL) implantation
may be associated with complications, including a high
degree of postoperative anterior chamber inflammation and
a higher risk of IOL dislocation or papillary capture, generally
as a result of excess gas tamponade and/or poor compliance
to positioning [68]. Therefore, the decision of the combined
versus the two-step procedure should be individualized
according to the characteristics of each case and the patient’s
and surgeon’s preferences.
3.4. Results of Surgery forMHandComplications. In the study
of the Moorfields Macular Hole (MMHS) Group [69], an
overall closure rate of 81% at 2 years was achieved in MHs
stages 2, 3, and 4 as well as an improvement in visual acuity
of 6/36 to 6/18, which was clearly superior to results obtained
in the observation group. In the Vitrectomy for Treatment of
Macular Hole Study (VMHS), the rate of anatomic closure
was 69% and the final visual acuity was higher in the operated
than in nonoperated eyes (20/115 versus 20/166) [70].
Once peeling of the ILM has become popular, closure
rates of 90% to 100%were reported [71–75]. However, the use
of indocyanine green was associated with potential toxicity
in some cases [76] and, for this reason, trypan blue and
brilliant blue are in widespread use in some countries, with
closure rates of 94% to 100%, without apparent severe side
effects [77–80]. Despite its clear indication and safety in MH
surgery, ILM peeling is a traumatic procedure that has acute
effects on the underlying retinal nerve fiber layer. ILMpeeling
often results in temporary swelling of the arcuate nerve fiber
layer (SANFL) which may be the earliest manifestation of
dissociated nerve fiber layer (DONFL) which occurs later in
the postoperative period. However it is probably a transient
feature that does not affect visual recovery [80].
Although peeling of the ILM has been widely adopted in
MH surgery, the high percentages of hole closure obtained
in the years prior to systematic ILM peeling add uncertainty
about whether to use it in all cases. Recently, Spiteri Cornish
et al. [81, 82] carried out a systematic review and meta-
analysis to assess the success of HM surgery with ILMpeeling
compared with the nonpeeling technique. Four randomized
clinical trials comparing both techniques were identified
[48, 49, 51, 81, 82]. There was no evidence of a difference in
the primary outcome (distance visual acuity at six months),
nor in distance visual acuity at 12 months between random-
ized groups. Overall, 66.2% achieved a visual acuity equal
or greater than 69 letters on ETDRS charts (corresponding
Snellen visual acuity 20/40) and 77.9%gainedmore than three
ETDRS lines. Improvement of visual acuity was higher in
patients in which primary anatomic closure was achieved
(final visual acuity 72.8±7.6 letters and a mean improvement
of 21.6±7.1 letters) than in eyes in which further surgery was
required (66.4 ± 8.6 and 17.4 ± 7.7 letters, resp.) [49].
However, visual improvement was obtained somewhat
earlier in the ILM peeling group and, at 3 months, improve-
ment was greater if ILM peeling was performed. In addition,
the percentage of primary closure was higher in the ILM
peeling as compared with no peeling (89.9% versus 50.3%,
with an odds ratio (OR) of 9.27 and 95% confidence interval
[CI] of 4.98–17.24). When reoperations were excluded from
the analysis, the ILM peeling group continued to have more
favourable results (OR 3.99, 95% CI 1.63–9.75). Also, in MH
stage 2, the efficacy rate was better for ILM peeling than no
peeling (91.6% versus 61.3%, with an OR of 6.19; 95% CI 1.65–
23.20) [48, 49, 83].
This higher success rate was not accompanied by an
increase of perioperative complications, neither in the reports
in which the ILM was stained with indocyanine green. In the
meta-analysis [81], the rate of intraoperative complications
was 19.32% for the ILM peeling group as compared with
21.1% for the nonpeeling group (OR 0.94, 95% CI 0.47–1.87).
The most frequent intraoperative complications were small
retinal hemorrhage (6–19%), retinal tears (5.4–32%), retinal
detachment (2–6%), and choroidal hemorrhage (0–3%).
According to these data, the authors conclude that ILM
peeling offers more favourable cost-effectiveness compared
with no peeling in MH surgery [81, 82].
3.5. Surgery-Related Prognostic Factors and Management of
Reopening. Although anatomic closure in MH surgery is
achieved in more than 90% of cases, sometimes it does not
correlate well with improvement in visual acuity. Multiple
studies using OCT have assessed hole configuration in an
attempt to establish a correlation with postoperative visual
acuity [84–91], emphasizing the importance of changes in
the outer retina. Kusuhara et al. [84] defined a macular hole
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index (MHI) as a ratio of hole height to base diameter of
hole, calculated from OCT transverse images of the macular
area, establishing that a MHI ≥0.5 was correlated with better
postoperative visual acuity than MIH <0.5. Ruiz-Moreno et
al. [85] described the diameter hole index (DHI) as a ratio
betweenminimumhole diameter and base diameter, showing
the minimum diameter was the best preoperative predictive
prognostic factor.
Different studies have shown a direct correlation between
integrity of the hyperreflective line as IS/OS junction of pho-
toreceptors and postoperative improvement of visual acuity.
In the study of Kitaya et al. [86], postoperative vision≥0.7 was
correlated with good reconstitution of the IS/OS junction.
However, Sano et al. [87] showed that a continuous IS/OS line
was not a reliable prognostic factor in the early postoperative
period given that abnormalities of the IS/OS line seen on SD-
OCT can be gradually repaired, with achievement of a contin-
uous IS/OS line at 6 months. Spaide and Curcio [88] assessed
the correlation of the outer retina analyzed by means of SD-
OCT and histopathological findings, showing that the hyper-
reflective line identified as IS/OS junction of photoreceptors
corresponded to the ellipsoid portion of the photoreceptor
inner segment, containing mitochondria. Wakabayashi et
al. [89] using SD-OCT described that reconstitution of the
external limiting membrane (ELM) was more important to
predict subsequent restoration of the foveal photoreceptor
layer than the ellipsoid zone restoration. Restoration of ELM
seems to be a necessary factor for reconstitution of the
ellipsoid band, with subsequent migration of photoreceptors
and complete closure of the full-thickness MH. Ruiz-Moreno
et al. [90] have analyzed 164 eyes with MH treated by
vitrectomy and ILM peeling showing that restoration of the
ellipsoid portion of the photoreceptor inner segment is an
important prognostic factor for visual rehabilitation afterMH
surgery.
Reopening of the hole (Figure 4) is one of the best known
complications after initially successful MH treatment with
vitreous surgery [67, 91–101]. Peeling of the ILM during
primaryMH surgery is one of the factors that has beenmostly
related to the incidence of reopening, varying between 0%
and 8% in eyes with ILM peeling [67, 95–97] and between
2% and 16% in eyes with no peeling [67, 93–95, 97]. The
variable percentages reported in the studies are due in part
to differences in the length of follow-up, with higher rates
associated with prolonged follow-up periods. Paques et al.
[93] reported a 9.5% incidence with a mean follow-up of 2
years, whereas Scott et al. [94] found a 12% incidence with a
mean follow-up of 7 years. Kumagai et al. [95] analyzed the
results of surgery in a series of 877 cases of MH, increasing
the reopening percentage to 28.1% with no ILM peeling. The
incidence of recurrence was 0.39% in eyes with peeling of the
ILM, increasing to 7.2% with no peeling. Besides no peeling,
statistically significant risk factors for reopening weremyopia
of more than 6 diopters and intraoperative retinal tears.
Retinal tears treated with laser may be one of the factors
that increase the development of ERM, with subsequent
tangential traction and reopening of the MH.
No peeling of the ILM may be associated with a higher
risk of ERM formation [92, 93, 97, 100]. Yoshida and Kishi
[97] observed the presence of ERM in all cases of reopening
of the hole. However, Kumagai et al. [95] did not report ERM
in none of the cases with hole reopening assessed by SD-OCT.
In relation to the incidence of reopening with bilateral
MH, Duker et al. [92] reported bilateral reopening in 38% of
cases, Christmas et al. [99] in 59%, Scott et al. [94] in 38%,
and Kumagai et al. in 14.9% [95].
Cataract surgery in the postoperative period of MH
surgery has been involved in the reopening of MH. Paques et
al. [93] observed that 73% of cases of hole reopening occurred
after a secondary cataract surgery. Bhatnagar et al. [67]
reported that in the presence of cystic macular edema after
secondary cataract surgery, there was a sevenfold increase
in the risk of reopened holes, and Garćıa-Arumı́ et al. [101]
reported recurrence of MH reopening after posterior capsu-
lotomy.However, other authors, includingKumagai et al. [95]
and Sheidow and Gonder [102] reported cystoid edema in
combined surgical procedures and that the incidence of hole
reopening did not increase in secondary cataracts.
With regard to treatment of persisting MH, ILM peeling
and ERM removal should be performed in those cases in
which these procedures were not performed at the initial
macular surgery, together with long-acting gas tamponade
(C3F8) and strict face-down positioning during the first
postoperative days. In these patients, the anatomic and
functional success is high.When ILM peeling and removal of
the ERMhave been performed in the first surgical procedure,
the success of reoperation decreases. In a series of 30 patients
reported by D’Souza et al. [103] with initial ILM peel who
underwent repeat surgery involving vitrectomy, enlargement
of ILM rhexis, and gas tamponade with C3F8, the anatomic
closure rate was 88% for primary surgery and 46.7% for
reoperation. More extensive ILM peeling causing tangential
traction due to fibrosis of dissection margin may contribute
to the anatomic closure. The use of growth factors, such
as platelet-derived growth factors as a stimulus of glial
progenitor cells, may be useful if the ILMhas been adequately
peeled (Figure 5), as well as the use of heavy silicone oil in
patients with positioning difficulties [104].
4. Practical Considerations:
Therapeutic Algorithm
Based on the aforementioned data and as shown in the
schematic representation in Figure 6, patients with VMA
can be observed without the need of any intervention. In
cases of VMT it is crucial to take into account the patient’s
symptoms. If the patient is asymptomatic, a follow-up control
at 3monthsmay be sufficient. During this interval, the patient
should be advised to perform periodic self-examinations
with the Amsler grid or monocular reading tests. In case
of symptoms, intensity and disability should be assessed.
There is no consensus criterion regarding the degree of vision
loss that should be considered significant and amenable
to treatment. However, in the TG-MV-006 y TG-MV-007
clinical trials, patients with visual acuity equal or lower than
20/25were eligible [20], so that this level of visual impairment
can be already considered to be susceptible of treatment. Also,
other causes that may justify decreased visual acuity should
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Figure 4: (a) Fundus photography and OCT of a patient who underwent macular hole surgery with ILM peeling and adequate reconstitution
of the outer retina (ELM and ellipsoid bands) and visual acuity 20/30. (b) Reopening of theMH after 3 years with cystoid edema surrounding
the hole and decreased visual acuity to 20/200. The ERM is not observed.
(a) (b)
Figure 5: Fundus photography andOCT after reoperation using platelet-derived growth factors. Successful anatomic hole closure is observed
but glial type scar in the inner retina and the absence of a continuous ellipsoid band determined a final visual acuity of 20/60.
be excluded. Metamorphopsia clinically significant for the
patient and visual loss progression are also key factors at the
time of adopting a more interventional therapeutic attitude.
Despite these considerations, a period of observation may be
an option for these patients, because spontaneous resolution
is still possible. In case of deciding an active treatment,
the presence of other associated macular diseases, such as
ERM, should be excluded [20]. When traction is ≤1500𝜇m,
enzymatic vitreolysis with ocriplasmin is the treatment of
choice. In the presence of>1500 𝜇mtraction or ERM, surgical
treatment with vitrectomy is associated with better outcomes
[105].
In cases with a full-thickness MH, it is necessary to assess
the diameter size. In cases of holes ≤400 𝜇m in size with
MVT and in the absence of ERM, enzymatic vitreolysis with
ocriplasmin is again themost recommendable option [20]. In
cases of holes >400𝜇m, or in the absence of evident VMT, or
in the presence of ERM, vitrectomy is the first option [105].
Patients undergoing enzymatic vitreolysis with intravit-
real injection of ocriplasmin should be evaluated at 7 and
30 days. Most cases of VMT or MH resolve within the first
week of treatment [20] and also at this time the occur-
rence of potential treatment-related complications should
be excluded. If resolution of VMT and/or hole closure had
not occurred after a month of treatment, the likelihood
of success is highly improbable and vitrectomy can be
performed. Patients with lamellar MH or pseudomacular
holes in which traction is usually absent are also candidates
for enzymatic vitreolysis. In cases of VMT associated with
other retinal diseases, such as age-related macular degen-
eration, diabetic macular edema, or vitreomacular interface
pathology in the myope, it is still too early to make a
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Figure 6: Treatment algorithm for VMA, VMT, and MH (VA: visual acuity, ERM: epiretinal membrane).
recommendation on the impact of enzymatic vitreolysis with
ocriplasmin in the treatment of these conditions, and we
should await for results of ongoing clinical trials on this topic
[106].
Finally, in all cases, the final decision regarding treatment
with enzymatic vitreolysis with ocriplasmin or vitrectomy
should be consensuated with the patient. All cases in which
the use of ocriplasmin is considered a first treatment option
can be successfully treated by means of vitrectomy. Also,
it may be possible that patients who initially are not ideal
candidates for enzymatic vitreolysis may have their patho-
logic condition solved by treatment with ocriplasmin [20].
Favourable prognostic factors for the choice of vitreolysis
have been identified including young age and phakic status,
but difficulties to maintain postoperative face-down posture
or the waiting lists for vitrectomy are variables that should
also be considered.
5. Conclusions
Enzymatic vitreolysis based on the intravitreal injection of
ocriplasmin is a treatment option with proven efficacy and
adequate safety profile in selected patients with VMT and
MH. In cases ofVMT, treatmentwith ocriplasmin is indicated
when traction is ≤1500 𝜇m and in the absence of concurrent
macular diseases (ERM). In the case ofMH, the hole diameter
should be ≤400, traction has to be present, and ERM should
be absent. When resolution of the process after one month of
the procedure is not achieved, vitrectomy with ILM peeling
would be the surgical treatment of choice.
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